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IN the present study we examined whether endothelin-1
stimulation of human monocytes causes release of
chemotactic factors. It was found that monocytes re-
leased neutrophil- and monocyte-chemotactic activity in
a dose- and time-dependent manner in response to ET-1.
ET-1 did not show any chemotactic activity by itself. NCA
was detected in monocyte supernatants in response to
ET-1 (0.01- 100 riM) after 1, 4, 8 and 24 h stimulation.
MCA was detected only after 24 h stimulation with ET-1
(0.1- 100 nM). Preincubation of the monocyte cultures
with the lipoxygenase inhibitors nordihydroguaiaretic
acid (10-4 M) or diethylcarbamazine (10-9 M) completely
abolished the appearance of NCA and MCA. NCA was
neutralized by > 75% using a polyclonal antibody against
human interleuktn-8. The ET-1 induced release of IL-8
was confirmed by IL-8 EHSA. A monoclonal antibody
against human monocyte chemotactic protein-1 neutral-
ized MCA by > 80%. It is concluded that ET-1 stimulation
of monocytes in vitro causes release of neutrophil- and
monocyte-chemotactic activity identified as IL-8 and
MCP-I respectively. An intact lipoxygenase pathway is
crucial for this effect of ET-1 to occur.
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Introduction
Endothelin-1 is a 21-amino acid peptide, initially
isolated from endothelial cells and described as the
most potent biological vasoconstrictor known. 1," It
has recently been shown that ET-1 also might acti-
vate monocytes and macrophages, causing release
of tumour necrosis factor-(x (TNF00, interleukin-l
(IL-11) and interleukin-6 (IL-6).
When activated, monocytes release several
chemotactic factors for monocytes and neutrophils.
Some chemotactic factors such as TNF0t and
leukotriene B (LTB4) show chemotactic activity for
both monocytes and neutrophils,4,5 while
interleukin-8 (IL-8) has chemotactic activity for
neutrophils and lymphocytes, but not for
monocytes6. Monocyte chemotactic protein-1 (MCP-
1) has specific chemotactic and activating activity for
monocytes.7
To further examine the pro-inflammatory effects of
ET-1, human monocytes in vitro were stimulated
with ET-1 for different time intervals, and the
supernatants tested for monocyte- and neutrophil
chemotactic activity. To identify the factors responsi-
ble for the chemotactic activity, neutralization experi-
ments with antibodies against known chemotactic
factors were performed. For comparison, super-
natants from ET-1 stimulated human endothelial cells
were also tested for chemotactic activity.
Methods
Isolation and cultivation ofmonocytes Highly purified
monocytes were obtained using the method de-
scribed previously*. Briefly, unseparated mono-
nuclear cells (PBMC) were isolated from human A
blood buffy coat (The Blood Bank, University Hos-
pital of Tromso, Norway) by density centrifugation
with Lymphoprep (Nycomed Pharma AS, Oslo, Nor-
way). The cells were washed three times with HBSS
(Gibco, Glasgow, UK) and resuspended in medium
consisting of RPMI-1640 with 100 IU/ml penicillin,
100 l.tg/ml streptomycin and supplemented with 25%
A human serum (The Bloodbank, University Hospi-
tal of TromsO). The peripheral blood mononuclear
cells (PBMC) were then seeded in 24-well culture
plates (Falcon, Becton Dickinson Labware, NJ, USA)
at concentration 2 x 106 cells/well. After incubation
at 37C for 90 min the cell cultures were washed
three times with pre-warmed RPMI-1640 to remove
non-adherent cells. The monocyte cultures were
stimulated with endothelin-1 (ET-1) (Nova Biochem,
Laufelingen, Switzerland) immediately. For chemo-
taxis assay, PBMC resuspended in RPMI-1640 supple-
mented with 2% human serum, 1 x 106 cells/ml were
used. The purity of the monocyte preparations was
assessed morphologically with Wright’s stain show-
ing > 80% monocytes. Their viability was > 95% as
assessed by Trypan blue exclusion.
()1994 Rapid Communications of Oxford Ltd Mediators of Inflammation Vol 3 1994 155E. Helset, T. Sildnes and Z. S. Konopski
Isolation ofhuman neutrophils: Neutrophils for use in
chemotaxis assay, were isolated from heparinized
blood from healthy adult donors by density centrifu-
gation with Polyprep (Nycomed Pharma AS, Oslo,
Norway), as described. Contaminating erythrocytes
were lysed with 0.2% NaCl for 60 s. The cells were
kept on ice, washed and resuspended at 1 x 106/ml
in RPMI-1640 supplemented with 2% human serum
and used immediately in experiments. The purity of
the neutrophil preparations was > 95% as assessed
morphologically with Giemsa staining, and the vi-
ability was > 98% tested by Trypan blue exclusion.
Stimulation of monocyte cultures with ET-I: The
monocyte cultures were stimulated with various con-
centrations of ET-1 ranging between 0.005 nM and
100 nM for 1, 4, 8 and 24 h. As control, RPMI-1640
instead of ET-1 was used in each experiment. The
supernatants were harvested at the indicated time
points and stored at-20C before being assayed for
neutrophil- and monocyte chemotactic activity.
To exclude possible contamination with
endotoxin, boiling of ET-1 for 30 min, which
denaturates the peptide but leaves endotoxin intact,
was used in stimulation experiments. In some experi-
ments ET-1 was preincubated with ET-1 antiserum
prior to addition to the cell cultures. In addition,
supernatants and ET-1 were tested by Endospecy
(Seikagaku Kogyo, Tokyo, Japan).
Preparation ofendothelial cell cultures and stimulation
with ET-I: Primary cultures of endothelial cell
monolayers (ECM) were prepared from human um-
bilical veins according to the method of Jaffe et al.
with slight modifications.9,1 Endothelial cells,
0.9 x 106, were grown in medium 199E.. 11 (Gibco
Ltd, Middlesex, UK) containing heat-inactivated foe-
tal calf serum (FCS) (Gibco) and 0.2 M t-glutamine
(Gibco). The endothelial cell cultures were stimu-
lated with various concentrations of ET-1 ranging
between 0.005 nM and 100 nM for 24 h. The
supernatants were harvested and analysed for
chemotactic activity.
Chemotaxis assay: The chemotaxis assay was per-
formed in a 48-well chemotaxis chamber
(Neuroprobe Inc., Cabin John, MD, USA) as de-
scribed previously.
11 The bottom wells of the cham-
ber were filled with 25 l-tl of supernatant in duplicate
or triplicate. A polyvinyl pyrrolidone (PVP)
polycarbonate filter (Neuroprobe Inc., Cabin John,
MD, USA) with a pore size of 5 l.tm for monocyte
chemotaxis, or a 5m PVP free polycarbonate filter
12
for neutrophil chemotaxis assay was placed over the
bottom wells. The upper wells were filled with 50 l.tl
of cell suspension. The chamber was then incubated
in humidified air in 5% CO2 at 37C for either 40 min
for neutrophil chemotaxis assay or 3 h for monocyte
chemotaxis assay. After incubation the chamber was
disassembled, and the filter was fixed in 2.5%
glutaraldehyde (Merck, Darmstadt, Germany), 0.1 M
sucrose, and 0.1 M cacodylate buffer, pH 7.3, for 30
min at room temperature. The filter was then stained
with 1% Giemsa (Sigma) for 30 min, and mounted on
a glass slide. Cells completely migrated through the
filter were counted in 6-12 high power fields (HPF,
x 100). Chemotactic response was expressed as the
mean number of cells per one HPF in duplicate or
triplicate wells. RPMI-1640 was used to determine
background migration. Formyl-methionyl-leucyl-
phenylalanine (FMLP, Sigma) at a concentration of
10 -7 M, was used as positive control.
Neutralization studies: In the neutralization studies,
supernatants from monocytes stimulated with ET-1
for different time intervals were incubated with a
polyclonal goat anti-human IL-8 antibody (British
Biotechnology, UK); or a monoclonal anti-human
TNF0t antibody (Boehringer Mannheim, Germany);
or a monoclonal anti-human MCP-1/MCAF antibody
(PeproTech Inc., NJ, USA) for 1 h at 37C, before
being tested for neutrophil and monocyte
chemotactic activity. Controls were performed using
non-immune serum. Anti-human IL-8 antibody, 1
mg/ml, was used at an initial dilution of 1:75 in the
experiments. Anti-human TNF0t antibody, 200 t.tg/ml,
was used at an initial dilution of 1:50. Anti-human
MCP-1/MCAF antibody, 1 mg/ml, was used at an
initial dilution of 1:50 in the experiments. The
decrease in chemotaxis was expressed as the per-
centage decrease in migration after addition of the
neutralizing antibody ([before antibody-after anti-
body] x 100 / [before antibody]).
IL-8 ELISA: Supernatants from monocytes stimulated
with ET-1 for different time intervals, were analysed
for IL-8 content by interleukin-8 ELISA (Quantikine
kits, British Biotechnology). A NovaPathTM Mini
Reader (BioRad, Richmond, CA, USA) was used in
reading of the microplates at OD45o.
Effect of lipoxygenase inhibitors on release of
NCA and MCA The lipoxygenase inhibitors
nordihydroguaiaretic acid (NDGA, 50 l.tM-400 lttM,
Sigma) or diethylcarbamazine (DEC, 0.62 nM-10 nM,
Sigma) was added to the monocyte cultures 5 min
before ET-1. The cell cultures were incubated at 37C
for different time intervals as described above, and
the supernatants were collected and examined for
NCA and MCA. The effect on NCA was examined
after 1, 4, 8 and 24 h incubation, while the effect on
MCA was examined after 24 h incubation. NDGA or
DEC did not affect monocyte viability as tested by
Trypan blue exclusion.
Statistics: The difference between groups was tested
for significance using a Student’s t-test, or one-way
ANOVA supplied with Scheffe’s test. 13 In all cases, a
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FIG. 1. (A) Dose dependent release of neutrophil chemotactic activity in response to ET-1 from human monocytes after 4 h stimulation. Shadowing
represents the response to FMLP 10 M. C: controls, supernatants from monocytes incubated with RPMI-1640 instead of ET-1. (B) Release of neutrophil
chemotactic activity in response to 0.5 nM ET-1 as a function of time.FM, ET-1 stimulated cells, i, controls. Results are presented as mean S.E.M. (n 8).
p < 0.05 compared with controls.
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FIG. 2. (A) Dose dependent release of monocyte chemotactic activity in response to ET-1 from human monocytes after 24 h stimulation. Shadowing
represents the response to FMLP 10 M. C: controls, supernatants from monocytes incubated with RPMI-1640 instead of ET-I. (B) Release of monocyte
chemotactic activity in response to 100 nM ET-1 as a function of time.[], ET-1 stimulated cells. I controls. Results are presented as mean + S.E.M. (n 8).
*p < 0.05 compared with controls.
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p value < 0.05 was considered significant. Data in the
figures and tables are expressed as mean _+ S.E.M.
Results
Release ofneutrophil (NCA) and monocyte chemotactic
activity (MCA)from ET-1 stimulated monocytes Mono-
cytes released NCA in response to ET-1 in a biphasic
manner as shown in Fig. 1A. The maximum response
was measured at 0.5 nM ET-1. This was comparable
to the NCA seen in response to FMLP 10 -7 M. ET-1
concentrations lower than 0.01 nM gave no signifi-
cant increase in NCA. Background migration, in re-
sponse to RPMI-1640 was 6.2 +_ 3.2 neutrophils/HPF.
The time course study (Fig. 1B) showed that the
release of NCA was significant by 1 h after addition
of ET-1, with a maximal response measured after 4 h,
and a further increase after 24 h stimulation.
Monocytes released MCA in response to ET-1 in a
dose dependent manner as shown in Fig. 2A. The
maximum response was seen after stimulation with
100 nM ET-1. This was comparable to the MCA seen
in response to FMLP 10 -7 M. Background migration,
in response to RPMI-1640, was 7.2 +_ 5.1 monocytes/
HPF. The time course study showed that the release
of MCA was significantly increased in the monocyte
supernatants only after 24 h stimulation with
ET-1.
No significant amounts of endotoxin were de-
tected in the supernatants or ET-1 used in the experi-
ments. Furthermore, denaturation of ET-1 by boiling,
or preincubation of ET-1 with ET-1 antiserum prior to
addition to the cell cultures, neutralized the ET-1
induced release of chemotactic activity.
No release ofMCA or NCA was observed from ET-
1 stimulated endothelial cell cultures compared with
Table 1. Effect of ET-1 on IL-8 release from human monocytes
in vitro
Concentration of ET-1 (M) Concentration of IL-8 (ng/ml)
h 4h 24h
None (controls) 0.7 + 0.0 0.7 + 0.0 1.4 + 0.1
10-1 1.4 + 0.1 2.2 + 0.0 2.4 + 0.0
10 -8 1.0 + 0.1 2.0 + 0.1 2.8 + 0.1
Supernatants from monocytes were stimulated with ET-1 for
different time intervals and examined for their IL-8 content using an
IL-8 ELISA kit. The results are presented as mean +/- S.D. of
triplicate determinations. The results are from one donor, and are
representative of three independent experiments with different
donors.
background migration (RPMI-1640) (data not
shown). ET-1 was not toxic for endothelial cells at
any concentration, as assessed by release of lactate
dehydrogenase (LDH) (data not shown). No changes
in endothelial cell morphology were observed by
light microscopic examination.
Immunoadsorption of monocyte and neutrophil
chemotactic activity: Incubation with an antibody
against IL-8 (dilution 1/100) reduced NCA in the
supernatants by > 75% (Fig. 3). The migration after
addition of antibody was not significantly different
from controls incubated with medium only; 22_+ 3
cells/HPF. Higher antibody concentrations did not
increase the inhibition of NCA, while lower antibody
concentrations showed a significant reduction in
inhibitory effect (data not shown). Release of IL-8
from ET-1 stimulated monocytes was further con-
firmed using IL-8 ELISA as shown in Table 1.
Incubation with a monoclonal antibody against
MCP-1 (dilution 1/200) reduced MCA by > 80% (Fig.
4). The migration after addition of antibody was not
significantly different from controls incubated with
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FIG. 3. Anti-human IL-8 antibody neutralized neutrophil chemotactic activ-
ity (NCA) in supernatants from ET-1 stimulated monocytes. Samples from
ET-1 stimulated cells were treated with control antibody or anti-lL-8 anti-
body and NCA was assessed. Data represent mean +/- S.E.M. (n= 6).
Open bars: samples; shaded bars: sample plus control antibody; closed
bars: sample plus anti-human IL-8 antibody. *p < 0.05 compared with
samples not incubated with antibody.
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FIG. 4. Anti-human MCP-1 antibody neutralized monocyte chemotactic
activity (MCA) in supernatants from ET-1 stimulated monocytes. Samples
from ET-1 stimulated cells were treated with control antibody or anti-MCP-
antibody and MCA was assessed. Data represent mean +/- S.E.M. (n 6).
Open bars, samples; shaded bars, sample plus control antibody; closed
bars, sample plus anti-human MCP-1 antibody. *p< 0.05 compared with
samples not incubated with antibody.Endothelin-1 stimulates monocytes to release chemotactic activity
Table 2. The effect of the lipoxygenase-inhibitors NDGA and
DEC on the ET-1 induced release of neutrophil and monocyte
chemotactic activity from human monocytes in vitro
NCA MCA
(cells/HPF) (cells/HPF)
Controls 13 +/- 4 8 +/- 2
Sample 55 +/- 6 40 +/- 7
NDGA, 50 IM 26 +/- 5* 20 +/- 4*
DEC, 2.5 nM 20 +/- 6* 12 +/- 5*
"The monocyte cultures were preincubated with NDGA or DEC
before ET-1 was added. Controls represent monocyte cultures
incubated with RPMI-1640 instead of ET-1. ’Sample’ represents the
response to 0.1 nM ET-1 and 100 nM ET-1 for release of NCA and
MCA, respectively. Results are presented as mean +/- S.E.M.
(n=8). *p < 0.05 compared with sample response. One-way
ANOVA supplied with Scheffe’s test.
medium, 18 _+ 4 cells/HPF. Higher antibody concen-
trations did not significantly increase the inhibition
ofMCA, while lower antibody concentrations signifi-
cantly reduced the inhibitory effect (data not shown).
Incubation with an antibody against TNFx showed
no neutralizing effect on MCA or NCA (data not
shown).
Effect oflipoxygenase inhibitors on release ofmonocyte-
and neutrophil chemotactic activity: ET-1 has been
shown previously to activate the arachidonic acid
cascade system in macrophages.
14 Therefore we
wanted to determine the possible contribution of
lipoxygenase pathway for the ET-1 induced release
ofNCA and MCA. As shown in Table 2 NCA and MCA
were significantly reduced when the monocytes
were incubated with one of the lipoxygenase in-
hibitors, NDGA or DEC, before ET-1 was added.
The reduction was dependent on the dose of
lipoxygenase inhibitor used, and was independent
of incubation time (data not shown). NDGA and DEC
alone did not show any NCA or MCA.
Discussion
In the present study it is shown that ET-1 functions
as a signal molecule for monocytes causing release of
chemotactic factors for neutrophils and monocytes.
The dose-response pattern for NCA with a maximal
response at an ET-1 concentration of 10-10M is simi-
lar to the dose-response pattern previously observed
for release of TNFa, IL-lb and IL-6 from monocytes
and macrophages. Viability tests, however, excluded
the possibility that higher concentrations of ET-1 had
a toxic effect on the cells. The striking difference in
dose-response and the time course for NCA and
MCA indicated that different chemotactic factors
for neutrophils and monocytes were produced in
response to ET-1. This was confirmed in
immunoadsorption studies showing that specific
antibodies against IL-8 neutralized the neutrophil
chemotactic activity, while monoclonal antibodies
against MCP-1 neutralized the monocyte chemotactic
activity. Although these antibodies neutralized MCA
and NCA by > 80% and > 75% respectively, we can-
not exclude the possibility that other chemotactic
factors are released after stimulation of monocytes
with ET-1.
A significant increase in IL-8 secretion was demon-
strated at all time-points measured. This time course,
with rapidly induced and long-lasting release
of IL-8, is in accordance with previous observations
on IL-8 release from activated mononuclear
phagocytes.6,15a6 Although monocytes are determined
to be the predominant producing cells for IL-8, vas-
cular endothelial cells have also been shown to
produce IL-8 when stimulated with lipopoly-
saccharide or TNF and IL-1. In the present study no
NCA is released from endothelial cells in response to
ET-1, indicating a disparate regulation of IL-8 release
from monocytes and endothelial cells.
The monocyte chemotactic activity, which was
neutralized with monoclonal antibodies against
MCP-1, was observed in the supernatants only after
24 h stimulation with ET-1. This is in accordance with
previous time course studies on MCP-1 release from
activated monocytes, showing a maximal response in
MCP-1 production after 24 h. 1,17 MCP-1 was recently
shown to be responsible for the majority of the
chemotactic activity released from vascular endo-
thelium. TM However, the present results show that
ET-1 causes no release of monocyte chemotactic
activity from endothelial cells.
Preincubation of the monocytes with the
lipoxygenase inhibitors NDGA and DEC, inhibited
the release of both monocyte and neutrophil chemo-
tactic activity. ET-1 has previously been reported not
to release LTB from monocytes, 19 while ET-1 stimu-
lation of alveolar macrophages causes release of
arachidonic acid. 14 Evidence is increasing that the
lipoxygenase pathway and lipoxygenase products
such as LWB might play a role of feedback regulators
or intracellular messengers for production of
cytokines, including IL-8.,21 Thus the present results
indicate that an intact lipoxygenase pathway is cru-
cial for the ET-1 induced release of IL-8 and MCP-1.
ET-1 has previously been shown to cause a
leukocyte dependent increase in microvascular per-
meability in isolated rat lungs.= The mechanism for
the ET-1 induced lung injury might be explained by
a synergistic action of TNFx, IL-I[ and IL-8 from
monocytes and tissue macrophages, causing
neutrophil recruitment and increased microvascular
permeability.
7,1
Patients with atherosclerosis have increased
circulating levels of ET-1, which exhibit a positive
correlation with the extension of disease. 23 MCP-1
and IL-8 have also been detected in early vascular
lesions in atherosclerosis, predominantly localized to
tissue macrophages.2<2 On this background we
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suggest that released ET-1 at predilection sites for
atherosclerosis, ’3,26 might stimulate mono-cytes and/
or tissue macrophages in the vascular wall to release
MCP-1 and IL-8, and thus contribute to recruitment of
inflammatory cells into the vessel wall causing a
chronic inflammatory condition and finally
atherosclerosis. 18,23,24
To conclude, ET-1 stimulation of human
monocytes in vitro caused release of monocyte and
neutrophil chemotactic activity provided that an in-
tact lipoxygenase pathway was present. The
neutrophil- and monocyte chemotactic activity were
identified as IL-8 and MCP-1, respectively.
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